These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30405638)

  • 1. LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens.
    Brunetti G; Rizzi R; Storlino G; Bortolotti S; Colaianni G; Sanesi L; Lippo L; Faienza MF; Mestice A; Curci P; Specchia G; Grano M; Colucci S
    Front Immunol; 2018; 9():2459. PubMed ID: 30405638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIGHT/TNFSF14 regulates estrogen deficiency-induced bone loss.
    Brunetti G; Storlino G; Oranger A; Colaianni G; Faienza MF; Ingravallo G; Di Comite M; Reseland JE; Celi M; Tarantino U; Passeri G; Ware CF; Grano M; Colucci S
    J Pathol; 2020 Apr; 250(4):440-451. PubMed ID: 31990039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
    Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
    Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
    Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.
    Brunetti G; Rizzi R; Oranger A; Gigante I; Mori G; Taurino G; Mongelli T; Colaianni G; Di Benedetto A; Tamma R; Ingravallo G; Napoli A; Faienza MF; Mestice A; Curci P; Specchia G; Colucci S; Grano M
    Oncotarget; 2014 Dec; 5(24):12950-67. PubMed ID: 25460501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT.
    Hemingway F; Kashima TG; Knowles HJ; Athanasou NA
    Exp Mol Pathol; 2013 Apr; 94(2):380-5. PubMed ID: 23391709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.
    Sabokbar A; Mahoney DJ; Hemingway F; Athanasou NA
    Clin Rev Allergy Immunol; 2016 Aug; 51(1):16-26. PubMed ID: 26578261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems.
    Cafiero C; Gigante M; Brunetti G; Simone S; Chaoul N; Oranger A; Ranieri E; Colucci S; Pertosa GB; Grano M; Gesualdo L
    Nephrol Dial Transplant; 2018 Jan; 33(1):65-75. PubMed ID: 28992140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
    Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
    J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study.
    Petitprez V; Royer B; Desoutter J; Guiheneuf E; Rigolle A; Marolleau JP; Kamel S; Guillaume N
    Int J Lab Hematol; 2015 Feb; 37(1):29-35. PubMed ID: 24661393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis.
    Colucci S; Brunetti G; Cantatore FP; Oranger A; Mori G; Quarta L; Cirulli N; Mancini L; Corrado A; Grassi FR; Grano M
    J Pathol; 2007 May; 212(1):47-55. PubMed ID: 17370327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
    Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
    Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Enhanced Osteoclastogenesis in Alkaptonuria.
    Brunetti G; Tummolo A; D'Amato G; Gaeta A; Ortolani F; Piacente L; Giordano P; Colucci S; Grano M; Papadia F; Faienza MF
    Am J Pathol; 2018 Apr; 188(4):1059-1068. PubMed ID: 29353057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL).
    Nicholson GC; Malakellis M; Collier FM; Cameron PU; Holloway WR; Gough TJ; Gregorio-King C; Kirkland MA; Myers DE
    Clin Sci (Lond); 2000 Aug; 99(2):133-40. PubMed ID: 10918046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals.
    Korkosz M; Czepiel M; Guła Z; Stec M; Węglarczyk K; Rutkowska-Zapała M; Gruca A; Lenart M; Baran J; Gąsowski J; Błyszczuk P; Siedlar M
    BMC Musculoskelet Disord; 2018 Dec; 19(1):434. PubMed ID: 30522483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.